gsk glaxosmithkline - Search News

News

GSK buys liver drug from Boston Pharmaceuticals

GSK buys liver disease drug for up to $2 bn

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a common form of liver disease, in a deal worth up to $2 billion.

Law.com · 2d

GSK Calls on US Firm Again as it Agrees $2B Liver Drug Transaction

In recent years, the U.K.-listed pharma giant has called increasingly on U.S. law firms for its transactional work.

The Boston Globe · 2d

GSK buys liver drug from Boston Pharmaceuticals for up to $2 billion

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the promising field of liver therapies.

CNBCTV1846m

Fire in GSK Pharma unit disrupts production

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

TipRanks on MSN2d

GSK Advances Share Buyback Program with Recent Acquisition

GlaxoSmithKline (GSK) has announced the repurchase of 783,700 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part ...

Reduce GlaxoSmithKline Pharmaceuticals: target of Rs 2,600: ICICI Securities

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

Zacks Investment Research on MSN3d

Glaxo (GSK) Upgraded to Buy: Here's What You Should Know

Investors might want to bet on GSK (GSK), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

Applied Clinical Trials Online1d

iTeos and GSK Halt TIGIT Antibody Belrestotug Development After Phase II Trials Miss Efficacy Marks in NSCLC and HNSCC

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

GSK Pharma Q4 profit rises 35% to ₹263 crore on strong brand growth

GSK Pharma reports 35 per cent YoY rise in Q4FY25 profit led by gains in general medicines and vaccines; oncology launches ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results